BR112022009607A2 - Inibidores de akt para melhorar a persistência de células t quimericas - Google Patents

Inibidores de akt para melhorar a persistência de células t quimericas

Info

Publication number
BR112022009607A2
BR112022009607A2 BR112022009607A BR112022009607A BR112022009607A2 BR 112022009607 A2 BR112022009607 A2 BR 112022009607A2 BR 112022009607 A BR112022009607 A BR 112022009607A BR 112022009607 A BR112022009607 A BR 112022009607A BR 112022009607 A2 BR112022009607 A2 BR 112022009607A2
Authority
BR
Brazil
Prior art keywords
car
cells
cell
subject
persistence
Prior art date
Application number
BR112022009607A
Other languages
English (en)
Inventor
L Davila Marco
M Sebti Said
Original Assignee
H Lee Moffitt Cancer Ct & Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lee Moffitt Cancer Ct & Res filed Critical H Lee Moffitt Cancer Ct & Res
Publication of BR112022009607A2 publication Critical patent/BR112022009607A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A61K39/464412—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases (EC 2.)
    • C12N2501/727—Kinases (EC 2.7.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

INIBIDORES DE AKT PARA MELHORAR A PERSISTÊNCIA DE CÉLULAS T QUIMERICAS. A recaída na transferência de células adotivas de células CAR-T é frequentemente o resultado do desaparecimento das células CAR-T. É revelado neste documento um método para melhorar a terapia de células CAR-T em um indivíduo, compreendendo administrar a um indivíduo submetido à transferência de células adotivas de células CAR-T terapêuticas um inibidor de Akt em uma quantidade eficaz para aumentar a persistência das células CAR-T. Como consequência, um indivíduo tratado com uma combinação de células CAR-T e um inibidor de Akt tem menos probabilidade de recaída. Portanto, também é revelado neste documento um método para tratar um indivíduo, compreendendo a transferência adotiva para o indivíduo de uma quantidade eficaz de uma composição compreendendo uma célula CAR-T e a administração ao indivíduo de um inibidor de Akt em uma quantidade eficaz para aumentar a persistência das células CAR-T.
BR112022009607A 2019-11-18 2020-11-18 Inibidores de akt para melhorar a persistência de células t quimericas BR112022009607A2 (pt)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201962937028P 2019-11-18 2019-11-18
US201962937359P 2019-11-19 2019-11-19
US201962942662P 2019-12-02 2019-12-02
US201962944295P 2019-12-05 2019-12-05
US202062982480P 2020-02-27 2020-02-27
PCT/US2020/061107 WO2021102038A1 (en) 2019-11-18 2020-11-18 Akt inhibitors for enhancing chimeric t cell persistence

Publications (1)

Publication Number Publication Date
BR112022009607A2 true BR112022009607A2 (pt) 2022-10-18

Family

ID=75981019

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022009607A BR112022009607A2 (pt) 2019-11-18 2020-11-18 Inibidores de akt para melhorar a persistência de células t quimericas

Country Status (11)

Country Link
US (1) US20230039099A1 (pt)
EP (1) EP4061383A4 (pt)
JP (1) JP2023503061A (pt)
KR (1) KR20220130100A (pt)
CN (1) CN115175686A (pt)
AU (1) AU2020387407A1 (pt)
BR (1) BR112022009607A2 (pt)
CA (1) CA3162094A1 (pt)
IL (1) IL293094A (pt)
MX (1) MX2022005973A (pt)
WO (1) WO2021102038A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117479949A (zh) * 2021-05-19 2024-01-30 预见疗法有限公司 产生改进的免疫细胞的群体的方法
CN113943710B (zh) * 2021-09-17 2023-03-24 浙江大学医学院附属第一医院 一种car-t细胞培养用的培养基及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016341966A1 (en) * 2015-10-20 2018-05-10 Kite Pharma, Inc. Methods of preparing T cells for T cell therapy
US11479755B2 (en) * 2015-12-07 2022-10-25 2Seventy Bio, Inc. T cell compositions

Also Published As

Publication number Publication date
EP4061383A1 (en) 2022-09-28
MX2022005973A (es) 2022-09-09
WO2021102038A1 (en) 2021-05-27
JP2023503061A (ja) 2023-01-26
AU2020387407A1 (en) 2022-07-07
IL293094A (en) 2022-07-01
CA3162094A1 (en) 2021-05-27
EP4061383A4 (en) 2024-03-27
CN115175686A (zh) 2022-10-11
US20230039099A1 (en) 2023-02-09
KR20220130100A (ko) 2022-09-26

Similar Documents

Publication Publication Date Title
EA202190630A1 (ru) Способы комбинированной терапии
BR112022009607A2 (pt) Inibidores de akt para melhorar a persistência de células t quimericas
MX2021013830A (es) Inhibidores de ezh2 para tratar linfomas.
BR112017010882B8 (pt) Compostos de n-((het)-arilmetil)-heteroaril-carboxamidas como inibidores de calicreína plasmática e seus usos
BR112018069251A2 (pt) métodos de intervenção precoce para prevenir ou melhorar a toxicidade
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
AU2018341571A8 (en) Therapeutic methods relating to HSP90 inhibitors
BR112017004349A2 (pt) terapia com gene de globina para o tratamento de hemoglobinopatias
BR112016014481A2 (pt) tratamento de câncer utilizando combinações de inibidores de erk e raf
BR112015013123A2 (pt) inibidores de beta-lactamase
BR112018007656A2 (pt) terapia de combinação para tratamento de doenças malignas
MX2019009227A (es) Métodos para tratar cáncer con inhibidores de hsp90.
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
BRPI0919020B8 (pt) uso de células de linhagem monocitária enriquecidas para tratar isquemia e para tratar angina pectoris
MX2021010173A (es) Compuestos con actividad inductora de ferroptosis y métodos de uso.
BR112015023439A2 (pt) combinação de tratamentos de câncer utilizando micrornas e inibidores egfr-tki
WO2018102687A3 (en) Combination therapy for treating cancer
BR112021022789A2 (pt) Métodos, sistemas e dispositivos para a seleção de pacientes para tl1a
BR112023002453A2 (pt) Composições de agente de via de estresse de replicação e métodos para tratar câncer
MX2021013608A (es) Composiciones y métodos de fabricacion de celulas t.
EP4063522A4 (en) COMPOSITION FOR PREDICTING RESPONSE TO STANDARD PREOPERATIVE CHEMORADIOTHERAPY AND POST-TREATMENT PROGNOSIS, AND METHOD AND COMPOSITION FOR PREDICTING PATIENTS LIKELY TO HAVE VERY UNSATISFACTORY PROGNOSES AFTER STANDARD THERAPY
BR112022001341A2 (pt) Inibidores de enzima
BR112017003552A2 (pt) ?métodos para tratar caquexia, para tratar saciedade precoce, para aumentar o tempo de sobrevida, para melhorar a qualidade de vida e para aumentar a massa corporal total?
CR20210514A (es) USO DE REBOXETINA PARA EL TRATAMIENTO DE NARCOLEPSIA (Divisional 2021-0183)
MX2023006542A (es) Inhibidores de la vía cinasa jano 1 (jak1) para el tratamiento del vitiligo.